Skip to main content
Premium Trial:

Request an Annual Quote

TrimGen Seeks FDA Clearance for Warfarin PGx Kit

NEW YORK (GenomeWeb News) – Molecular diagnostics firm TrimGen said today that it has filed with the US Food and Drug Administration for 510(k) clearance of its diagnostic kit to aid physicians in prescribing the anticoagulant warfarin.
 
The firm’s eQ-PCR LightCycler Warfarin Genotyping Kit identifies certain SNPs in the CYP2C9 and VKORC1 genes, which serve as clinically relevant predictors of warfarin dosing. The test is run on Roche’s LightCycler platform.
 
According to Sparks, Md.-based TrimGen, results of more than 5,000 tests during clinical trials showed 100 percent agreement between its warfarin kits and the corresponding bi-directional sequencing method.
 
Several firms sell home-brew molecular diagnostic ASRs for warfarin dosing, and many have said they would seek FDA clearance for their tests.
 
Thus far, Nanosphere is the only firm to receive FDA clearance of a test for warfarin sensitivity.
 
Nanosphere’s Verigene Warfarin Metabolism Nucleic Acid Test, which runs on the company’s Verigene platform, was cleared in September and also detects some variants of the CYP2C9 and VKORC1 genes.
 
In August, the FDA updated labeling for warfarin with information explaining that people with variations in CYP2C9 and VKORC1 may respond differently to the drug. The agency, however, stopped short of requiring physicians to genetically test their patients, noting that additional outcomes studies needed to be done.
 

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.